Pilot Award Recipient: Conrad Russell Cruz, MD, PhD

Dr. Conrad R Cruz

Secretion of Enhaned Engineered Antibodies by Antigen-specific T-Cells for Tripartite Elimination of the HIV Reservoir

April 15, 2020

Although HIV infection can be controlled by daily lifelong adherence to expensive antiretroviral therapies it cannot presently be cured. Eradicating virus from a person will likely require the co-ordination of drugs that expose hidden viral reservoirs (latency reversing drugs) with the effective harnessing of multiple arms of the immune system. We are developing a potentially curative therapeutic platform of engineered killer T-cells that, upon triggering by latency reversing drugs, will direct three arms of the immune system against the viral reservoirs that the drugs will simultaneously expose.